SCHEMBL757416

SCHEMBL757416

CC(=O)Nc1nccc(Cl)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.47
POLB P06746 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
PRNP P04156 1/20 0.45
GAA P10253 1/20 0.45
KMT2A Q03164 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
CYP1A2 P05177 2/20 0.44
AURKB Q96GD4 1/20 0.44
CDK4 P11802 1/20 0.44
CCNE1 P24864 1/20 0.44
CDK2 P24941 1/20 0.44
PTK2 Q05397 1/20 0.43
MAPK14 Q16539 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
CDC7 O00311 1/20 0.42
JAK2 O60674 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21508445 0.84 KDM4E (0.43) KDM4EKMT2ANPC1RAB9AL3MBTL1
SCHEMBL4543263 0.83 CYP1A2 (0.56) AURKAPOLBKDM4EMEN1PRNP
SCHEMBL20447560 0.83 KDM4E (0.44) AURKAPOLBKDM4EMEN1GAA
SCHEMBL15305786 0.79 KDM4E (0.46) POLBKDM4EMEN1PRNPGAA
SCHEMBL14298343 0.79 L3MBTL1 (0.54) POLBKDM4EMEN1PRNPGAA
SCHEMBL5629171 0.79 KDM4E (0.46) POLBKDM4EMEN1PRNPGAA
SCHEMBL17518970 0.78 ATR (0.53) ALDH1A1
SCHEMBL27654591 0.78 RAB9A (0.48) POLBKDM4EMEN1PRNPGAA
SCHEMBL1786698 0.77 KMT2A (0.47) AURKAPOLBKDM4EMEN1PRNP
SCHEMBL22186826 0.76 KDM4E (0.69) POLBKDM4EMEN1PRNPGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240417405-A1 Substituted Spiro Derivatives JANSSEN PHARMACEUTICA NV (BE) 2024-12-19 US disclosed
CN-117730081-A Substituted spirocyclic derivatives 詹森药业有限公司 2024-03-19 CN disclosed
EP-4334320-A1 SUBSTITUTED SPIRO DERIVATIVES JANSSEN Pharmaceutica NV (BE) 2024-03-13 EP disclosed
WO-2022237627-A1 SUBSTITUTED SPIRO DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2022-11-17 WO disclosed
CN-108947970-B Indazole derivative and preparation method and application thereof 四川大学 2022-04-05 CN disclosed
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
EP-1307454-B1 DERIVATIVES OF VARIOLIN B PHARMA MAR SA (ES) 2009-06-03 EP disclosed
CN-100424083-C Pyrimidine derivative compound and its preparing method GUANGXI NAT UNIV (CN) 2008-10-08 CN disclosed
US-7329666-B2 Derivatives of variolin B PHARMA MAR, S.A. (ES) 2008-02-12 US disclosed
US-20080033001-A1 Derivatives of Variolin B UNIVERSIDAD DE BARCELONA (ES) 2008-02-07 US disclosed
US-20080033001-A1 Derivatives of Variolin B UNIVERSIDAD DE BARCELONA (ES) 2008-02-07 US disclosed
US-20080033001-A1 Derivatives of Variolin B UNIVERSIDAD DE BARCELONA (ES) 2008-02-07 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
CN-1935805-A Pyrimidine derivative compound and its preparing method GUANGXI NAT UNIV (CN) 2007-03-28 CN disclosed
CN-1275965-C Derivatives of variolin b UNIV BARCELONA (ES) 2006-09-20 CN disclosed
US-20040058939-A1 Derivatives of variolin b PHARMA MAR, S.A. (ES) 2004-03-25 US disclosed
CN-1468240-A Derivatives of variolin b �ϼ��������Ǵ�ѧ 2004-01-14 CN disclosed
EP-1307454-A1 DERIVATIVES OF VARIOLIN B Universidad de Barcelona (ES) 2003-05-07 EP disclosed
WO-2002012240-A1 DERIVATIVES OF VARIOLIN B UNIVERSIDAD DE BARCELONA (ES) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033001-A1 Derivatives of Variolin B ARG2, SDHB, OAT AURKA 638/4885POLB 1449/4885KDM4E 1443/4885
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 AURKA 479/4885POLB 3140/4885KDM4E 3676/4885
US-20040058939-A1 Derivatives of variolin b HNRNPA2B1, HNRNPAB, SYNCRIP AURKA 1034/4885POLB 1365/4885KDM4E 1485/4885
US-20240417405-A1 Substituted Spiro Derivatives BMI1, MLLT1, MLLT3 AURKA 3212/4885POLB 4059/4885KDM4E 671/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 AURKA 479/4885POLB 3140/4885KDM4E 3676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.